EP4168008
A COMBINATION OF BELZUTIFAN AND LENVATINIB FOR USE IN TREATING CANCER
Status:
EP einkaleyfi: EP einkaleyfi tilnefnt til gildistöku á ÍslandiEP appl. date:
21.6.2021EP published:
18.3.2026EP application number:
21828761.3
EPO information:
European Patent Register
Max expiry date:
20.6.2041Expiry date:
17.7.2026
Title in English:
A COMBINATION OF BELZUTIFAN AND LENVATINIB FOR USE IN TREATING CANCERLanguage of the patent:
English
Timeline
Today
21.6.2021EP application
18.3.2026EP Publication
17.7.2026Expires
Owner
Name:
Merck Sharp & Dohme LLCAddress:
126 East Lincoln Avenue, Rahway, New Jersey 07065, US
Name:
Eisai R&D Management Co., Ltd.Address:
6-10 Koishikawa, 4-Chome Bunkyo-Ku, Tokyo 112-8088, JP
Inventor
Name:
PERINI, Rodolfo FleuryAddress:
North Wales, Pennsylvania 19454-2505, US
Name:
PINHEIRO, Elaine, M.Address:
Boston, Massachusetts 02115-5727, US
Name:
WILLEMANN ROGERIO, JaquelineAddress:
Rahway, New Jersey 07065-0907, US
Priority
Number:
202063042307 PDate:
22.6.2020Country:
US
Number:
202163146915 PDate:
8.2.2021Country:
US
Classification
Categories:
A61K 31/47, A61K 31/277, A61P 35/04